GEN Exclusives

More »

GEN News Highlights

More »
May 30, 2007

Cervical Cancer Vaccine Is Goal of Intas and Virionics Alliance

  • Intas Biopharmaceuticals and Virionics are partnering for development of an HPV vaccine for cervical cancer. The development of the HPV therapeutic (HPV-16 & HPV-18) will be based on the Virionics’ Virus-Like Particle technology.

    The collaboration provides for technology transfer and exclusive marketing rights to Intas for supply of the product in India and certain other key markets.

    “The companies will jointly initiate a development program and create a development committee, comprising members of the two companies, which will be responsible for creating, modifying, and monitoring the program,” explains Shri Mani Iyer, director at Intas. “The committee will be responsible for providing strategic preclinical, manufacturing, and clinical study and simultaneously executing a clinical program to support the combination product. Additionally, Intas will have the first option to be a contract manufacturing supplier of the product, for India and other markets. Process development and yield improvement activities will be carried out at Intas.”


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »